Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia

NCT05656027 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

469

Enrollment

OTHER

Sponsor class

Conditions

Presbyopia
Refractive Error
Eye Diseases
Near Vision

Interventions

DRUG: Aceclidine+Brimonidine combination ophthalmic solution
DRUG: Aceclidine ophthalmic solution
DRUG: Brimonidine

Sponsor

LENZ Therapeutics, Inc